Equities analysts forecast that Amneal Pharmaceuticals, Inc. (NYSE:AMRX) will announce $502.23 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Amneal Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $477.70 million and the highest estimate coming in at $520.70 million. Amneal Pharmaceuticals reported sales of $397.33 million during the same quarter last year, which indicates a positive year over year growth rate of 26.4%. The business is expected to announce its next earnings report before the market opens on Friday, February 26th.
On average, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.99 billion for the current financial year, with estimates ranging from $1.96 billion to $2.00 billion. For the next financial year, analysts anticipate that the business will report sales of $2.04 billion, with estimates ranging from $1.96 billion to $2.08 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Amneal Pharmaceuticals.
Several analysts recently issued reports on the company. Barclays upgraded Amneal Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $4.50 to $6.00 in a report on Monday, December 14th. SVB Leerink reiterated a “hold” rating and issued a $5.50 price target on shares of Amneal Pharmaceuticals in a report on Tuesday, December 15th. Zacks Investment Research downgraded Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 17th. Finally, Guggenheim upgraded Amneal Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $5.50 price target for the company in a report on Monday, December 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.06.
Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Amneal Pharmaceuticals by 10.1% during the third quarter. JPMorgan Chase & Co. now owns 36,973 shares of the company’s stock valued at $142,000 after acquiring an additional 3,391 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Amneal Pharmaceuticals by 7.9% during the third quarter. GSA Capital Partners LLP now owns 53,864 shares of the company’s stock worth $209,000 after purchasing an additional 3,963 shares during the last quarter. Raymond James & Associates lifted its position in shares of Amneal Pharmaceuticals by 3.9% during the third quarter. Raymond James & Associates now owns 174,229 shares of the company’s stock worth $676,000 after purchasing an additional 6,465 shares during the last quarter. LPL Financial LLC lifted its position in shares of Amneal Pharmaceuticals by 40.2% during the fourth quarter. LPL Financial LLC now owns 23,635 shares of the company’s stock worth $108,000 after purchasing an additional 6,775 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $27,000. Institutional investors own 33.49% of the company’s stock.
NYSE AMRX traded down $0.48 during trading hours on Thursday, hitting $4.88. The company had a trading volume of 80,672 shares, compared to its average volume of 1,303,343. Amneal Pharmaceuticals has a fifty-two week low of $2.40 and a fifty-two week high of $6.18. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of 11.59, a P/E/G ratio of 0.29 and a beta of 1.27. The company has a debt-to-equity ratio of 8.20, a current ratio of 2.31 and a quick ratio of 1.60. The firm’s 50 day moving average is $5.12 and its 200 day moving average is $4.49.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Article: Diluted Earnings Per Share
Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.